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Adjusted Clopidogrel Loading Doses
According to Vasodilator-Stimulated
Phosphoprotein Phosphorylation Index
Decrease Rate of Major Adverse Cardiovascular
Events in Patients With Clopidogrel Resistance
A Multicenter Randomized Prospective Study
Laurent Bonello, MD,* Laurence Camoin-Jau, MD, PHD,† Stéphane Arques, MD,‡ Christian Boyer, MD,§
Dimitri Panagides, MD, PHD, Olivier Wittenberg, MD,¶ Marie-Claude Simeoni, MD,#
Paul Barragan, MD,** Françoise Dignat-George, MD, PHD,† Franck Paganelli, MD, PHD*
Marseille, Aubagne, and Ollioules, France
Objectives This study evaluates the clinical impact of adjusting the loading dose of clopidogrel according to vasodilator-
stimulated phosphoprotein (VASP) index in patients with clopidogrel resistance undergoing percutaneous coro-
nary intervention (PCI).
Background Clopidogrel resistance plays a key role in ischemic recurrence after PCI. In vitro tests of clopidogrel resistance
can accurately predict major adverse cardiac events after PCI.
Methods In this prospective, randomized, multicenter study, clopidogrel resistance was defined as a VASP index of more
than 50% after a 600-mg loading dose. Patients with clopidogrel resistance undergoing coronary stenting were
randomized to a control group or to the VASP-guided group, in which patients received additional bolus clopi-
dogrel to decrease the VASP index below 50%.
Results A total of 162 patients were included. The control (n  84) and VASP-guided groups (n  78) had similar demo-
graphic, clinical, and biological characteristics. In the VASP-guided group, dose adjustment was efficient in 67
patients (86%) and VASP index was significantly decreased (from 69.3  10 to 37.6  13.8; p  0.001). Eight
major adverse cardiac events (5%) were recorded during the 1-month follow-up, with a significantly lower rate in
the VASP-guided group compared with the control group (0% vs. 10%; p  0.007). There was no difference in
the rate of major and minor bleeding (5% vs. 4%; p  1).
Conclusions This is the first study to suggest that adjusting the clopidogrel loading dose according to platelet monitoring us-
ing the VASP index is safe and may significantly improve the clinical outcome after PCI in patients with clopi-
dogrel resistance despite a first 600-mg loading dose. (J Am Coll Cardiol 2008;51:1404–11) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.044c
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ccepted December 17, 2007.oronary intervention (PCI) has become the most fre-
uently used form of coronary revascularization. Since the
id-1990s, stent deployment has been the gold standard to
educe the rate of acute closure (1) and in-stent restenosis
2,3). Addition of the P2Y12 adenosine diphosphate (ADP)
eceptor blocker, clopidogrel, to aspirin in patients under-
See page 1412
oing PCI has dramatically reduced the rate of major
dverse cardiac events (MACE) (4,5). However, not all
atients benefit to the same extent from these improvements
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April 8, 2008:1404–11 Platelet Monitoring in PCIn antiplatelet therapy, and some continue to suffer ischemic
ecurrences, including stent thrombosis, which are associ-
ted with significant mortality and morbidity (5,6). The
athophysiology of recurrent ischemic events is multifacto-
ial, although numerous reports have demonstrated that
lopidogrel resistance is a major precipitating factor (7–9).
In vitro tests of platelet reactivity, such as ADP-induced
latelet aggregometry and vasodilator-stimulated phosphopro-
ein (VASP) phosphorylation analysis, accurately detect bio-
ogical clopidogrel resistance, which is associated with worse
utcome after PCI (7–9). However, there is no consensus
n the definition of biological clopidogrel resistance, and its
revalence remains unclear. In a previous prospective study
n patients undergoing PCI, we observed that a cutoff value
f 50% in the VASP index was predictive of MACE at 6
onths. Using this threshold value, the test demonstrated a
ensitivity of 100% in predicting MACE of clinical interest
10). Cuisset et al. (11) reported in a recent prospective,
andomized, single-center study that increasing the clopi-
ogrel loading dose from 300 to 600 mg is likely to improve
linical outcome after coronary angioplasty. However, de-
pite the 600-mg loading dose, some patients remained
lopidogrel-resistant and the rate of MACE observed at 1
onth, although decreased, was still 5%.
Several reports have highlighted the large interindividual
esponse to clopidogrel, regardless of the test used to assess
latelet reactivity, and the optimal loading and maintenance
oses are still being debated (12,13). We hypothesized that
he loading dose may need to be individually adjusted
ccording to the patient’s biological response to clopidogrel
o decrease the rate of MACE after stenting. We conducted
his study to evaluate the clinical benefit of adjusting the
lopidogrel loading dose according to platelet reactivity, as
ssessed by the VASP index, to the rate of MACE in
atients undergoing stenting who presented clopidogrel
esistance despite a first 600-mg loading dose.
ethods
his was a multicenter, prospective, controlled, randomized
tudy. The study protocol was in accordance with the
eclaration of Helsinki and was approved by the local ethics
ommittees of our institutions. All patients gave written
nformed consent before inclusion.
All patients undergoing PCI for refractory angina pecto-
is under optimal medical therapy, silent ischemia on
hallium scintigraphy, or non–ST-segment elevation myo-
ardial infarction (NSTEMI) were eligible for inclusion.
xclusion criteria were persistent ST-segment elevation
yocardial infarction, a failed PCI, New York Heart
ssociation functional class III or IV, sudden death, con-
raindications to antiplatelet therapy, platelet count 100
/l, history of bleeding diathesis, and concurrent severe
llness with expected survival of 1 month.
The VASP index was measured 24 h after the first
00-mg bolus of clopidogrel. All patients with a VASPndex above 50% were prospec-
ively included in the study and
ere randomly assigned to the
ontrol group or to the VASP-
uided group.
In the control group, PCI was
arried out without an additional
olus of clopidogrel. In the
ASP-guided group, the overall
ose of clopidogrel was adjusted
ndividually, before PCI, to ob-
ain a VASP index below 50%.
riefly, after the initial dose up
o 3 additional boluses of 600 mg
ay be given in 24 h increments,
nd the VASP index was as-
essed 12 h after administration
ntil a VASP index below 50%
as obtained (Fig. 1). If these
dditional boluses were unable to decrease the VASP index
elow 50%, PCI was performed without further loading-
ose adjustment.
ngioplasty procedure. The PCI was carried out accord-
ng to international guidelines, using a standard technique,
hrough the femoral route (14). Systematic stent implanta-
ion was achieved in all patients. Either a drug-eluting or
are-metal stent could be used according to French Society
f Cardiology guidelines. The sheath was removed imme-
iately at the end of the procedure in all cases. Routine care
efore and after the procedure was undertaken for all
Figure 1 Study Design
VASP  vasodilator-stimulated phosphoprotein.
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
MACE  major adverse
cardiac events
MFI  mean fluorescence
intensity
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
TIMI  Thrombolysis In
Myocardial Infarction
VASP  vasodilator-
stimulated phosphoprotein
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Platelet Monitoring in PCI April 8, 2008:1404–11atients, including pre-treatment clopidogrel (600-mg ini-
ial bolus) 12 h before the procedure followed by 75 mg
aily for at least 1 month. In addition, all patients received
spirin, 160 mg daily, for at least 1 month, with a dose
dministered 12 h before stenting.
For patients with NSTEMI, anticoagulation with unfrac-
ionated heparin was begun in the intensive care unit before
CI. Glycoprotein IIb/IIIa inhibitors were administered at
he discretion of the interventional cardiologist and were
sed according to guidelines (15).
The interventional cardiologist and the treating physician
ere not aware of the VASP index results at the time of
CI.
lood samples. Blood samples for VASP phosphorylation
nalysis were drawn by atraumatic venipuncture of the
ntecubital vein. The initial blood drawn was discarded to
void measuring platelet activation induced by needle punc-
ure; blood was collected into a Vacutainer (BD, Franklin
akes, New Jersey) containing 3.8% trisodium citrate and
lled to capacity. The Vacutainer was inverted 3 to 5 times
or gentle mixing and sent immediately to the hemostasis
aboratory.
ASP phosphorylation analysis. The VASP phosphory-
ation analysis was performed within 24 h of blood collec-
ion by an experienced investigator using Platelet VASP kits
Diagnostica Stago, Asnières, France) according to the
anufacturer’s instructions (7,10). Briefly, blood samples
ere incubated in vitro with ADP and/or prostaglandin E1
PGE1) before fixation. Each sample was indirectly immu-
olabeled by incubation with 16C2 monoclonal antibody
ollowed by staining with a goat antimouse fluorescein
sothiocyanate polyclonal reagent (BioCytex, Marseille,
rance). Flow cytometric analysis was performed using a
oulter EPICS XL cytometer (Beckman Coulter Inc.,
ullerton, California). Platelet population was identified on
ts forward and side scatter distributions and 3,000 platelet
vents were gated and analyzed for mean fluorescence
ntensity (MFI) using EPICS XL software. The MFI
orresponding to each experimental condition (ADP, ADP
PGE1) was determined to establish a ratio directly
orrelated with the VASP phosphorylation state. The ratio,
00  [(MFIPGE1  MFIADPPGE1)/MFIPGE1], is ex-
ressed in this study as a VASP phosphorylation index
VASP index) corresponding to a ratio of the VASP
hosphorylation of activated platelets versus resting platelets
nd expressed as a percentage of platelet reactivity. The
ntra-assay coefficient of variation was 5%, and the inter-
ssay coefficient of variation was 8%. The normal platelet
eactivity in healthy subjects is above 70% (16).
nd points. End points were recorded by an investigator
ho was not aware of the treatment status and clinical
haracteristics of patients. The primary end point was the
ate of MACE (defined in the next section). Secondary end
oints, recorded to assess safety, were major and minor
leeding. Major bleeding was defined as intracranial bleed-
ng or clinically-overt bleeding associated with a decrease in oemoglobin of 5 g/dl, according to the Thrombolysis In
yocardial Infarction (TIMI) criteria (17). Minor bleeding
as also defined according to TIMI criteria (17).
ACE. Clinical follow-up was performed 1 month after
CI. Events recorded included cardiovascular death,
ngiographically-confirmed stent thrombosis, recurrent
cute coronary syndrome as defined by the American
ollege of Cardiology/American Heart Association guide-
ines (14), and recurrent revascularization by either coronary
ngioplasty or bypass surgery.
We defined stent thrombosis using the Academic Re-
earch Consortium classification (18) as an angiographic
onfirmation of stent thrombosis associated with at least 1
f the following signs present within 48 h: new onset of
schemic symptoms at rest, recent changes suggestive of
cute ischemia on resting electrocardiogram, or typical rise
nd fall in cardiac biomarkers. Stent thrombosis was further
haracterized as acute (0 to 24 h) or subacute (1 day and
30 days).
Drug therapy compliance was assessed. The treating
hysician and the investigators who evaluated the clinical
nd points were blinded to the results of platelet testing and
o group assignment.
ower calculation. We postulated that the average differ-
nce in the rate of MACE between the 2 groups would be
5% (0% vs. 15%) (10). Therefore, for 90% power and an
lpha risk of 5%, we estimated that 76 patients should be
ncluded in each group. We estimated that 5% of patients
ould be lost to follow-up, so the target number of included
atients was 160.
tatistical analysis. Statistical analysis was performed us-
ng SPSS 15 software (SPSS Inc., Chicago, Illinois). Con-
inuous variables are expressed as mean  standard devia-
ion. Categorical variables are expressed as frequency and
ercentage. Comparison between categorical variables was
erformed using the chi-square test or Fisher exact test
hen frequencies were below 5. Analysis of variance was
sed to compare characteristics of quantitative variables.
aplan-Meier curves were used to assess MACE-free
urvival.
esults
atients. From March to July 2007, 406 consecutive pa-
ients admitted for PCI to 4 participating cardiology centers
n Marseille were prospectively screened for inclusion. A
otal of 244 patients were not included: 78 met exclusion
riteria and 166 (48%) had a VASP index below 50% after
he first 600-mg bolus of clopidogrel. Therefore, 162
atients undergoing coronary angioplasty with stent im-
lantation fulfilled the inclusion criteria. Eighty-four pa-
ients were randomized to the control group. Seventy-eight
atients were randomized to the VASP-guided group and
eceived up to 3 additional loading doses in an attempt to
btain a VASP index below 50% (Fig. 1).
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April 8, 2008:1404–11 Platelet Monitoring in PCIBaseline characteristics are summarized in Table 1. De-
ographic data and body mass index were similar in the 2
roups. The prevalence of cardiovascular risk factors was
imilar, including diabetes and smoking (p  0.7 and 0.4,
espectively). The PCI indications were balanced among the
inclusion criteria and were similar between the 2 random-
zed groups. The rate of patients undergoing PCI for
STEMI was similar (48% vs. 45%; p 0.7). The 2 groups
id not differ in left ventricular ejection fraction (p  0.7).
he PCI data were also similar including the number of
rug-eluting stents per patient and stent length (p  0.9
nd 0.1, respectively). Consistent with the study protocol,
here is a significant difference in the time between the first
lopidogrel loading dose and performance of PCI (26  3 h
aseline Characteristics
Table 1 Baseline Characteristics
Cont
(n
Gender, female/male 1
Age, yrs* 66.6
BMI, kg/m2* 27.2
Previous myocardial infarction, n (%) 2
History of CABG, n (%) 1
Cardiovascular risk factors, n (%)
Present smoking 3
Dyslipidemia 4
Diabetes mellitus 3
Hypertension 5
Family history of CAD 1
Treatment on admission
Beta-blocker 3
Aspirin 4
Statin 4
PCI indication, n (%)
Silent ischemia 1
Stable angina 2
NSTEMI 4
Angiography and intervention
LVEF, %* 59.4
Number of diseased vessels* 2.1
Number of treated vessels* 1.4
Number of stents per patient* 2
Number of DES per patient* 0.96
Stent length per patient, mm* 29
GP IIb/IIIa inhibitors, n (%) 1
Biology
Time between first LD and VASP measurement, h* 24.5
VASP after first loading dose, %* 67.8
VASP after sensitization, %*
Hemoglobin, g/dl* 13.8
Leucocytes, g/l* 7.8
Platelets, 103 g/l* 240
Fibrinogen, g/l* 3.8
Creatinine, mol/l* 93
Mean  SD. †p  0.0001 between VASP after first loading dose and VASP after sensitization.
BMI body mass index; CABG coronary artery bypass graft; CAD coronary artery disease; D
Imyocardial infarction; NSTEMI non–ST-segment elevation myocardial infarction; PCI percs. 65  24 h; p  0.0001). rlatelet parameters. The mean time between the first
oading dose of clopidogrel and blood sampling was similar
n the 2 groups (24.5  13.1 h vs. 23.6  13 h; p  0.7)
Table 1). The VASP index after the first loading dose of
lopidogrel was also similar (67.8  10.5 vs. 69.3  10; p 
.7).
Figure 2 summarizes the effect of each additional clopi-
ogrel loading dose on the VASP index in patients random-
zed to the VASP-guided group. After the second bolus of
lopidogrel, 38 patients had a VASP index below 50% and
he mean VASP index was significantly decreased from
aseline (50.5  17.3 vs. 69.3  10; p  0.001). Forty
atients required a third loading dose of clopidogrel. Fol-
owing this, 26 patients (65%) were still resistant and
up
)
VASP-Guided Group
(n  78) p Value
19/59 0.5
.1 66.3 10.1 0.9
27.6 5.1 0.6
22 (28) 0.5
6 (8) 0.4
27 (35) 0.4
41 (53) 0.9
31 (40) 0.7
47 (60) 1
21 (27) 0.1
29 (37) 0.9
44 (56) 0.5
41 (53) 0.6
14 (18) 0.6
27 (35) 0.7
35 (45) 0.7
.1 58.7 13.2 0.7
2.4 1.3 0.1
1.5 0.7 0.4
2.2 1.2 0.3
0.97 1.1 0.9
33 18 0.1
13 (17) 0.6
.1 23.6 13 0.7
.5 69.3 10 0.4
37.6 13.8† —
13.4 1.5 0.5
7.5 2.5 0.5
230 76 0.4
3.9 1 0.5
98 37 0.4
rug-eluting stents; GP glycoprotein; LD loading dose; LVEF left ventricular ejection fraction;
s coronary intervention; SD standard deviation; VASP vasodilator-stimulated phosphoprotein.rol Gro
 84
7/67
 11
 5.1
0 (24)
0 (12)
5 (42)
5 (54)
6 (43)
1 (61)
4 (17)
2 (38)
3 (51)
1 (49)
8 (21)
7 (32)
0 (48)
 12
 1.1
 0.6
 1
 1.1
 15
7 (20)
 13
 10
—
 5.4
 2.3
 68
 1
 43equired a fourth loading dose to achieve the target VASP
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Platelet Monitoring in PCI April 8, 2008:1404–11ndex. Additional loading doses were unable to decrease the
ASP index below 50% in 11 patients (14% of patients
andomized to the VASP-guided group). The mean VASP
ndex after sensitization in the VASP-guided group was
7.6  13.8% (p  0.0001, vs. after first loading dose).
linical outcomes. One-month follow-up was completed
n all patients. Eight (5%) MACE occurred during
ollow-up (Table 2), all in the control group (10%) (Fig. 3),
esulting in a statistically significant difference between the
roups (p  0.007). The distribution of cardiovascular
vents is summarized in Table 2.
emorrhagic complications and side effects of clopi-
ogrel. There was 1 major hemorrhagic complication in
ach group: an intracranial bleed requiring surgery in the
ontrol group and a femoral hematoma requiring transfu-
ions in the VASP-guided group (Table 3). The overall rate
f bleeding was similar in the 2 groups (5% vs. 4%, p  1).
o other side effect of clopidogrel was reported.
iscussion
he data from this multicenter prospective study suggest
hat adjusting the clopidogrel loading dose according to the
ASP index among patients with clopidogrel resistance
ho were undergoing coronary stenting may significantly
Figure 2 Effects of Each Additional Bolus of Clopidogrel
on the VASP Index in the VASP-Guided Group
VASP 1 is the VASP index after the initial loading dose as given to patients in
both groups; VASP 2 is that after the second loading dose, and so on. Abbrevi-
ation as in Figure 1.
rimary End Points:ACE During 1-Month Follow-Up
Table 2 Primary End Points:MACE During 1-Month Follow-Up
End Point
Control
Group
VASP-Guided
Group
Cardiovascular death, n (%) 2 (2) 0
Acute stent thrombosis, n (%) 1 (1) 0
Subacute stent thrombosis, n (%) 3 (4) 0
Recurrent acute coronary syndrome, n (%) 2 (2) 0
All MACE, n (%) 8 (10)* 0p  0.007.
MACE  major adverse cardiac events; other abbreviation as in Table 1. Amprove clinical outcome. To our knowledge, this is the first
andomized study to demonstrate the clinical benefit of
rospective platelet monitoring of clopidogrel efficiency in
atients undergoing stenting.
In the present study, we used the VASP index to monitor
latelet reactivity. The original VASP assay described by
chwarz et al. (16) was modified by Barragan et al. (7) to
rack VASP phosphorylation using a flow cytometric assay
o establish a ratio directly correlated with VASP phosphor-
lation state. This VASP index, expressed as a mean
ercentage of platelet reactivity, is inversely correlated with
lopidogrel efficiency. In their retrospective study, Barragan
t al. (7) observed a strong correlation between subacute
tent thrombosis and a VASP index higher than 50%. These
esults were later confirmed in a prospective study, and the
0% threshold demonstrated a very high negative predictive
alue for MACE after PCI (11). Moreover, Blindt et al. (19),
n a prospective study, observed that a VASP index above 48%
as the only independent predictor of stent thrombosis in
igh-risk PCI. In a recent experimental study to track the
ntithrombotic effects of clopidogrel in rats, Schumacher et al.
Figure 3 Kaplan-Meier Analysis for 30-Day MACE
Kaplan-Meier analysis for 30-day major adverse cardiovascular (CV) events
(MACE) according to group. Log-rank  7.75, p  0.005. Blue  control group;
red  VASP-guided group. Abbreviation as in Figure 1.
econdary End Points:leeding During 1-Month Follow-Up
Table 3 Secondary End Points:Bleeding During 1-Month Follow-Up
End Point
Control
Group
VASP-Guided
Group
Major bleeding, n (%) 1 1
Minor bleeding, n (%) 3 (4) 2 (3)
All, n (%) 4 (5) 3 (4)bbreviation as in Table 1.
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April 8, 2008:1404–11 Platelet Monitoring in PCI20) demonstrated that a 50% VASP index corresponded to a
early 90% P2Y12 receptor blockage.
Current common clinical practice consists of pre-
reatment with a 300-mg loading dose of clopidogrel at least
h before the procedure in patients undergoing PCI for
arious clinical indications (15). In 1 study (11), the prev-
lence of clopidogrel resistance after the standard 300-mg
oading dose was 75% using the VASP index, but a 600-mg
oading dose was associated with a faster and greater
ntiplatelet effect, reducing the rate of patients with resis-
ance (21–25). In the present study, the 600-mg loading
ose significantly decreased the rate of patients with resis-
ance to 52%. Two recent studies also suggest a better
linical outcome in the setting of coronary stenting with a
00-mg loading dose compared with a 300-mg dose (9,26).
evertheless, the rate of MACE at 1 month was still 5%
espite the increased loading dose (9).
Considering the difficulty in identifying patients resistant
o clopidogrel, we hypothesized that the clopidogrel loading
ose should be individually adjusted according to a platelet
unction assay. Because of the very high sensitivity and the
eproducibility of the 50% threshold, the VASP index
llows simple platelet monitoring. Gurbel et al. (27) dem-
nstrated that the VASP index is strongly correlated with
DP-induced platelet aggregometry, which is considered
he gold standard.
The ADP-induced platelet aggregometry definition of
no response” is not consensual and corresponds for Gurbel
t al. (21) to a 10% decrease in absolute change in
ggregation. This definition is based on platelet responsive-
ess and not on post-treatment platelet reactivity, which has
een advocated by recent studies (9,11) on the topic and was
sed in this study. Moreover, in contrast to the VASP
ndex, the predictive value of this biologically-derived
hreshold is unknown. Because of these different definitions
f resistance, it is possible that some of the patients classified as
low responders” when using ADP-induced platelet aggre-
ometry may be classified as “nonresponders” when using the
ASP index. The data in the present study concur in that the
ate of nonresponders is higher than previously reported with a
00-mg loading dose using ADP-induced platelet aggregom-
try (21). This could also be related to the high proportion of
atients with NSTEMI, a condition that is associated with an
ncreased prevalence of clopidogrel nonresponders (28). Fur-
hermore, as demonstrated by Morel et al. (29), ADP-induced
latelet aggregometry is sensitive to glycoprotein IIb/IIIa or
spirin administration and therefore may not identify all
onresponders.
Interestingly, most events in this study were angiographically-
roven stent thrombosis, a condition that is consistent with
nsufficient platelet inhibition by clopidogrel. The high
requency of this complication as well as the high overall
ose of clopidogrel required in the VASP-guided group are
robably linked to the selection of patients according to
esistance to the 600-mg clopidogrel loading dose and to the
ery high negative predictive value of the VASP index (11). aoreover, most patients had PCI for NSTEMI, which has
een associated with increased platelet activity and greater
revalence of clopidogrel resistance (29).
In this study, 2 MACE were recorded after the first 10
ays of follow-up in the control group. Although not
tatistically significant, this difference in the rate of MACE
nder chronic clopidogrel therapy may have several expla-
ations. In particular, it is possible that loading dose
djustment may provide a lasting sensitization to clopi-
ogrel. Moreover, reducing platelet reactivity during PCI
nd the first days after stent implantation may prevent
hrombus formation, avoiding later events. However, in this
tudy, the VASP index was not measured under chronic
lopidogrel therapy, and we cannot ascertain whether ad-
usting the clopidogrel loading dose allows for sustained
ensitization, thus preventing delayed events. The play of
hance could also be involved in this difference in event rates
ore than 10 days after dose adjustment.
Among patients with resistance to a 600-mg loading dose
f clopidogrel in the VASP-guided group, 14% remained
esistant despite an additional 1,800 mg of clopidogrel. The
rognosis in this subset of patients and their management
hould be addressed in future studies. Campo et al. (30)
emonstrated that ticlopidine could be an alternative treat-
ent because crossover resistance appears infrequently. New
DP antagonists, such as prasugrel, may also be useful in
uch patients.
Although the expected rate of events in this small subset
f patients was 15%, none were recorded. This may be
elated to the play of chance and to the multifactorial nature
f MACE. Furthermore, the sensitivity of the test may not
e as high as expected.
In the present study, we observed a clinical benefit from
djusting the clopidogrel loading dose according to post-
reatment platelet reactivity among patients with resistance
espite a 600-mg loading dose. Moreover, this was well
olerated and did not increase the rate of bleeding compli-
ations or other side effects of the drug. Our data validate
djusting the clopidogrel loading dose according to the
ASP index, before PCI, in daily clinical practice to
mprove the clinical outcome in coronary stenting. This
pproach is associated in this study with an increased length
f hospital stay. However, given the observed safety of the
ASP-guided loading dose of clopidogrel, dose adjustment
ould be realized before hospitalization for PCI.
tudy limitations. The sample size of the present study is
elatively small and therefore does not allow for definitive
onclusions. Further large multicenter studies are needed to
onfirm our results. Delaying PCI until dose adjustment
as performed may have induced a bias associated with
ime-dependent effects of other antianginal therapy. To
revent bias in future trials, inclusion of a placebo-
ontrolled group would correct for the time imbalance
etween the groups. The VASP phosphorylation analysis is
tandardized, reproducible, and accurate, but it is expensive
nd technically demanding, which limits its widespread use
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pproach should be evaluated in future trials.
onclusions
his is the first study suggesting that adjusting clopidogrel
oading dose according to platelet reactivity measured by
ASP index is safe and may significantly improve clinical
utcome after PCI in patients with clopidogrel resistance.
oreover, the very high sensitivity of the VASP index at a
utoff value of 50% may be considered of clinical interest in
voiding subacute stent thrombosis and may justify routine
onitoring for clopidogrel resistance in high-risk popula-
ion subsets.
cknowledgments
he authors thank the catheterization laboratory staff and
urses for their assistance, and Caroline, Marie, and Paul
onello for the time they devoted to this research. They
ould also like to thank Dr. Com and Dr. Amabile for their
articipation in the study. Finally, Sophie Rushton-Smith,
hD, provided editorial services in the preparation of this
anuscript.
eprint requests and correspondence: Dr. Laurent Bonello,
épartement de Cardiologie, Hôpital Universitaire Nord, Chemin
es Bourrely, 13015, Marseille, France. E-mail: laurentbonello@
ahoo.fr.
EFERENCES
1. Sigwart U, Urban P, Golf S, et al. Emergency stenting for acute
occlusion after coronary balloon angioplasty. Circulation 1988;78:
1121–7.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of
balloon-expandable-stent implantation with balloon angioplasty in
patients with coronary artery disease. Benestent Study Group. N Engl
J Med 1994;331:489–95.
3. Fischman DL, Leon MB, Baim DS, et al. Stent Restenosis Study
Investigators. A randomized comparison of coronary-stent placement
and balloon angioplasty in the treatment of coronary artery disease.
N Engl J Med 1994;331:496–501.
4. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind
study of the safety of clopidogrel with and without a loading dose in
combination with aspirin compared with ticlopidine in combination
with aspirin after coronary stenting: the Clopidogrel Aspirin Stent
International Cooperative Study (CLASSICS). Circulation 2000;102:
624–9.
5. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with
clopidogrel and aspirin followed by long-term therapy in patients
undergoing percutaneous coronary intervention: the PCI-CURE
study. Lancet 2001;358:527–33.
6. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month
clinical outcome of thrombotic stent occlusion after bare-metal,
sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;
45:947–53.
7. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopy-
ridines: clinical detection of coronary stent thrombosis by monitoring
of vasodilator-stimulated phosphoprotein phosphorylation. Catheter
Cardiovasc Interv 2003;59:295–302.8. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events inpatients with acute myocardial infarction. Circulation 2004;109:
3171–5.
9. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet
reactivity identified low-responders to dual antiplatelet therapy at
increased risk of recurrent cardiovascular events after stenting for acute
coronary syndrome. J Thromb Haemost 2006;4:542–9.
0. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated
phosphoprotein phosphorylation analysis prior to percutaneous coro-
nary intervention for exclusion of postprocedural major adverse car-
diovascular events. J Thromb Haemost 2007;5:1630–6.
1. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose
of clopidogrel on platelet reactivity and clinical outcomes in patients
with non–ST-segment elevation acute coronary syndrome undergoing
coronary stenting. J Am Coll Cardiol 2006;48:1339–45.
2. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for
coronary stenting: response variability, drug resistance, and the effect of
pretreatment platelet reactivity. Circulation 2003;107:2908–13.
3. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C.
Flow cytometric analysis of intraplatelet VASP phosphorylation for
the detection of clopidogrel resistance in patients with ischemic
cardiovascular diseases. J Thromb Haemost 2005;3:85–92.
4. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI
2005 guideline update for percutaneous coronary intervention: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Com-
mittee to Update the 2001 Guidelines for Percutaneous Coronary
Intervention). J Am Coll Cardiol 2006;47:e1–121.
5. Bertrand ME, Simoons ML, Fox KA, et al., for the Task Force on the
Management of Acute Coronary Syndromes of the European Society
of Cardiology. Management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation. Eur Heart J
2002;23:1809–40.
6. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry
analysis of intracellular VASP phosphorylation for the assessment of
activating and inhibitory signal transduction pathways in human
platelets—definition and detection of ticlopidine/clopidogrel effects.
Thromb Haemost 1999;82:1145–52.
7. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial
Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and
changes in plasma fibrinogen and the fibrinolytic system in patients
treated with recombinant tissue plasminogen activator and streptoki-
nase. J Am Coll Cardiol 1988;11:1–11.
8. O’Riordan M. New standard stent-thrombosis definition yields com-
parable event rates for DES and bare-metal stents. HeartWire [online
serial]. October 25, 2006. Available at: http://www.theheart.org/
article/749305.do. Accessed November 2006.
9. Blindt B, Stellbrink K, de Taeye A, et al. The significance of
vasodilator-stimulated phosphoprotein for risk stratification of stent
thrombosis. Thromb Haemost 2007;98:1329–34.
0. Schumacher WA, Bostwick JS, Ogletree ML, et al. Biomarker
optimization to track the antithrombotic and hemostatic effects of
clopidogrel in rats. J Pharmacol Exp Ther 2007;322:369–77.
1. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry
US. The relation of dosing to clopidogrel responsiveness and the
incidence of high post-treatment platelet aggregation in patients
undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392–6.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel
loading dose during coronary stenting: effects on drug response and
interindividual variability. Eur Heart J 2004;25:1903–10.
3. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati
A, Schomig A. Absorption, metabolization, and antiplatelet effects of
300-, 600-, and 900-mg loading doses of clopidogrel: results of the
ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regi-
men: Choose Between 3 High Oral Doses for Immediate Clopidogrel
Effect) trial. Circulation 2005;112:2946–50.
4. Montalescot G, Sideris G, Meuleman C, et al. A randomized
comparison of high clopidogrel loading doses in patients with non–
ST-segment elevation acute coronary syndromes: the ALBION (As-
sessment of the Best Loading Dose of Clopidogrel to Blunt Platelet
Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll
Cardiol 2006;48:931–8.
22
2
2
2
3
1411JACC Vol. 51, No. 14, 2008 Bonello et al.
April 8, 2008:1404–11 Platelet Monitoring in PCI5. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of
platelet inhibition after a 600-mg loading dose of clopidogrel in a
large, unselected cohort of candidates for percutaneous coronary
intervention. Circulation 2005;111:2560–4.
6. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio
G. Randomized trial of high loading dose of clopidogrel for reduction
of periprocedural myocardial infarction in patients undergoing coro-
nary intervention: results from the ARMYDA-2 (Antiplatelet therapy
for Reduction of MYocardial Damage during Angioplasty) study.
Circulation 2005;111:2099–106.
7. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of
clopidogrel responsiveness: measurements of maximum platelet aggre-
gation, final platelet aggregation and their correlation with vasodilator-
stimulated phosphoprotein in resistant patients. Thromb Res 2007;
121:107–15.8. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on
inhibition of platelet aggregation following clopidogrel loading in
patients undergoing coronary intervention: do we need more aggressive
dosing regimens in unstable angina? Catheter Cardiovasc Interv
2003;59:21–5.
9. Morel O, Viellard C, Faure A, et al. Platelet responsiveness to
clopidogrel in patients with coronary syndrome. Comparison of
platelet aggregation induced by ADP and flow cytometric analysis of
intraplatelet VASP phosphorylation. Ann Cardiol Angeiol 2007;56:
21–9.
0. Campo G, Valgimigli M, Gemmati D, et al. Poor responsiveness to
clopidogrel: drug-specific or class-effect mechanism? Evidence from a
clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol
2007;50:1132–7.
